Haploidentical Bone Marrow Transplantation in Primary Immune Deficiency: Stem Cell Selection and Manipulation

Immunology and Allergy Clinics of North America

Volumn 30, Issue 1, 2010, Pages 45-62

  Hagin, David ^a   Reisner, Yair ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Immunodeficiency; Stem cell transplantation; T cell depletion

Indexed keywords

ALEMTUZUMAB; CD34 ANTIGEN; CD4 ANTIGEN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; LECTIN; OKT 3; T LYMPHOCYTE RECEPTOR;

BLOOD DONOR; BONE MARROW TRANSPLANTATION; CD34 SELECTION; CD4+ T LYMPHOCYTE; CELL MANIPULATION; GRAFT VERSUS HOST REACTION; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SIBLING RELATION; SURVIVAL RATE; T CELL DEPLETION; TREATMENT OUTCOME;

ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HAPLOTYPES; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LYMPHOCYTE DEPLETION; MICE; RATS; STEM CELLS; T-LYMPHOCYTES;

EID: 74749096522     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2009.11.002     Document Type: Review

References (75)

1. Geha R.S., Notarangelo L.D., Casanova J.L., et al. The International Union of Immunological Societies (IUIS) primary immunodeficiency diseases (PID) classification committee. J Allergy Clin Immunol 120 4 (2007) 776
2. Buckley R.H. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 22 (2004) 625-655
3. Fischer A. Primary immunodeficiency diseases: an experimental model for molecular medicine. Lancet 357 9271 (2001) 1863-1869
4. Gatti R., Meuwissen H., Allen H., et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 2 7583 (1968) 1366
5. Bortin M., and Rimm A. Severe combined immunodeficiency disease. Characterization of the disease and results of transplantation. JAMA 238 7 (1977) 591-600
6. Reisner Y., Kapoor N., Kirkpatrick D., et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 2 8242 (1981) 327-331
7. Griffith L.M., Cowan M.J., Kohn D.B., et al. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol 122 6 (2008) 1087-1096
8. Zuckerman T., and Rowe J.M. Alternative donor transplantation in acute myeloid leukemia: which source and when?. Curr Opin Hematol 14 (2007) 152-161
9. Tiercy J.M., Bujan-Lose M., Chapuis B., et al. Bone marrow transplantation with unrelated donors: what is the probability of identifying an HLA-A/B/Cw/DRB 1/B 3/B 5/DQB 1-matched donor?. Bone Marrow Transplant (Basingstoke) 26 4 (2000) 437-441
10. Uphoff D. Preclusion of secondary phase of irradiation syndrome by inoculation of fetal hematopoietic tissue following lethal total-body x-irradiation. J Natl Cancer Inst 20 (1958) 625
11. Yunis E., Good R., Smith J., et al. Protection of lethally irradiated mice by spleen cells from neonatally thymectomized mice. Proc Natl Acad Sci U S A 71 6 (1974) 2544
12. Bortin M., and Saltzstein E. Graft-versus-host inhibition: fetal liver and thymus cells to minimize secondary disease. Transplantation 8 5 (1969) 712
13. Korngold B., and Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 148 6 (1978) 1687-1698
14. Reisner Y., Linker-Israeli M., and Sharon N. Separation of mouse thymocytes into two subpopulations by the use of peanut agglutinin. Cell Immunol 25 1 (1976) 129-134
15. Reisner Y., Ravid A., and Sharon N. Use of soybean agglutinin for the separation of mouse B and T lymphocytes. Biochem Biophys Res Commun 72 4 (1976) 1585-1591
16. Reisner Y., Itzicovitch L., Meshorer A., et al. Hemopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins. Proc Natl Acad Sci U S A 75 6 (1978) 2933-2936
17. Reisner Y., Ikehara S., Hodes M.Z., et al. Allogeneic hemopoietic stem cell transplantation using mouse spleen cells fractionated by lectins: in vitro study of cell fractions. Proc Natl Acad Sci U S A 77 2 (1980) 1164-1168
18. Reisner Y., Kapoor N., O'Reilly R., et al. Allogeneic bone marrow transplantation using stem cells fractionated by lectins: VI, in vitro analysis of human and monkey bone marrow cells fractionated by sheep red blood cells and soybean agglutinin. Lancet 2 8208-8209 (1980) 1320-1324
19. Reisner Y., Kapoor N., Good R., et al. Allogeneic bone marrow transplantation in mouse, monkey and man using lectin-separated grafts. In: Slavin S. (Ed). Tolerance in bone marrow and organ transplantation (1984), Elsevier Science Publishing Co, Amsterdam (NY) 293
20. Reisner Y., Kapoor N., Kirkpatrick D., et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 61 2 (1983) 341
21. O'Reilly R., Kapoor N., Kirkpatrick D., et al. Transplantation for severe combined immunodeficiency using histoincompatible parental marrow fractionated by soybean agglutinin and sheep red blood cells: experience in six consecutive cases. Transplant Proc 15 1 (1983) 1431
22. Friedrich W., Goldmann S.F., Vetter U., et al. Immunoreconstitution in severe combined immunodeficiency after transplantation of HLA-haploidentical, T-cell-depleted bone marrow. Lancet 1 8380 (1984) 761-764
23. Fischer A., Durandy A., De Villartay J., et al. HLA-haploidentical bone marrow transplantation for severe combined immunodeficiency using E rosette fractionation and cyclosporine. Blood 67 2 (1986) 444
24. Filipovich A.H., McGlave P.B., Ramsay N.K., et al. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet 1 8284 (1982) 1266-1269
25. Hayward A.R., Murphy S., Githens J., et al. Failure of a pan-reactive anti-T cell antibody, OKT 3, to prevent graft versus host disease in severe combined immunodeficiency. J Pediatr 100 4 (1982) 665-668
26. Hale G., Bright S., Chumbley G., et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 62 4 (1983) 873
27. Frame J.N., Collins N.H., Cartagena T., et al. T cell depletion of human bone marrow. Comparison of Campath-1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads. Transplantation 47 6 (1989) 984-988
28. Waldmann H., Hale G., Cividalli G., et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody(CAMPATH-1). Lancet 2 8401 (1984) 483-485
29. Apperley J., Jones L., Hale G., et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1 1 (1986) 53
30. Hale G., Cobbold S., and Waldmann H. T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation 45 4 (1988) 753
31. Hale G., Zhang M.J., Bunjes D., et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 92 12 (1998) 4581
32. Waldmann H., and Hale G. CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci 360 1461 (2005) 1707
33. Civin C.I., Strauss L.C., Fackler M.J., et al. Positive stem cell selection-basic science. Prog Clin Biol Res 333 (1990) 387-401 [discussion: 402]
34. Sutherland D.R., Stewart A.K., and Keating A. CD34 antigen: molecular features and potential clinical applications. Stem Cells 11 Suppl 3 (1993) 50-57
35. Shpall E.J., Gee A., Cagnoni P.J., et al. Stem cell isolation. Curr Opin Hematol 2 6 (1995) 452-459
36. Slatter M.A., Brigham K., Dickinson A.M., et al. Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency. J Allergy Clin Immunol 121 (2008) 361-367
37. Haddad E., Landais P., Friedrich W., et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 91 10 (1998) 3646
38. Buckley R.H., Schiff S.E., Schiff R.I., et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 340 7 (1999) 508-516
39. Small T.N., Friedrich W., and O'Reilly R.J. Hematopoietic cell transplantation for immunodeficiency diseases. In: Appelbaun F.R., Forman S.J., Negrin S., et al. (Eds). Thomas' hematopoietic cell transplantation. 4th edition (2009), Blackwell Publishing Ltd 1105-1124
40. Antoine C., Müller S., Cant A., et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 361 9357 (2003) 553-560
41. Grunebaum E., Mazzolari E., Porta F., et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 295 5 (2006) 508-518
42. Myers L.A., Patel D.D., Puck J.M., et al. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 99 3 (2002) 872
43. Bertrand Y., Landais P., Friedrich W., et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European Group for Bone Marrow Transplantation and the European Society for Immunodeficiency. J Pediatr 134 6 (1999) 740
44. Booth C., Hershfield M., Notarangelo L., et al. Management options for adenosine deaminase deficiency. Proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol 123 2 (2007) 139-147
45. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D., et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 111 1 (2008) 439
46. Filipovich A.H., Stone J.V., Tomany S.C., et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 97 6 (2001) 1598
47. Cowan M.J., Neven B., Cavazanna-Calvo M., et al. Hematopoietic stem cell transplantation for severe combined immunodeficiency diseases. Biol Blood Marrow Transplant 14 1S (2008) 73-80
48. Cavazzana-Calvo M., André-Schmutz I., Dal Cortivo L., et al. Immune reconstitution after haematopoietic stem cell transplantation: obstacles and anticipated progress. Curr Opin Immunol 21 (2009) 544-548
49. Scaradavou A., Carrier C., Mollen N., et al. Detection of maternal DNA in placental/umbilical cord blood by locus-specific amplification of the noninherited maternal HLA gene. Blood 88 4 (1996) 1494
50. Neven B., Leroy S., Decaluwe H., et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 113 17 (2009) 4114
51. Douek D.C., McFarland R.D., Keiser P.H., et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 396 6712 (1998) 690-695
52. Mackall C., Granger L., Sheard M., et al. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood 82 8 (1993) 2585
53. Dumont-Girard F., Roux E., van Lier R.A., et al. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood 92 11 (1998) 4464
54. Roux E., Helg C., Dumont-Girard F., et al. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 87 9 (1996) 3984
55. Small T., Papadopoulos E., Boulad F., et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 93 2 (1999) 467
56. Weinberg K., Blazar B.R., Wagner J.E., et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 97 5 (2001) 1458
57. Patel D.D., Gooding M.E., Parrott R.E., et al. Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 342 18 (2000) 1325-1332
58. Muller S.M., Kohn T., Schulz A.S., et al. Similar pattern of thymic-dependent T-cell reconstitution in infants with severe combined immunodeficiency after human leukocyte antigen (HLA)-identical and HLA-nonidentical stem cell transplantation. Blood 96 13 (2000) 4344
59. Lewin S.R., Heller G., Zhang L., et al. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood 100 6 (2002) 2235
60. Dulude G., Roy D.C., and Perreault C. The effect of graft-versus-host disease on T cell production and homeostasis. J Exp Med 189 8 (1999) 1329-1342
61. Hazenberg M.D., Otto S.A., de Pauw E.S., et al. T-cell receptor excision circle and T-cell dynamics after allogeneic stem cell transplantation are related to clinical events. Blood 99 9 (2002) 3449
62. Sarzotti M., Patel D.D., Li X., et al. T cell repertoire development in humans with SCID after nonablative allogeneic marrow transplantation 1. J Immunol 170 5 (2003) 2711-2718
63. Borghans J.A., Bredius R.G., Hazenberg M.D., et al. Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency. Blood 108 2 (2006) 763
64. Cavazzana-Calvo M., Carlier F., Le Deist F., et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood 109 10 (2007) 4575
65. Frey J., Ernst B., Surh C., et al. Thymus-grafted SCID mice show transient thymopoiesis and limited depletion of V beta 11 T cells. J Exp Med 175 4 (1992) 1067-1071
66. Haddad E., Deist F.L., Aucouturier P., et al. Long-term chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: a single-center study of 22 patients. Blood 94 8 (1999) 2923
67. Slatter M., Bhattacharya A., Flood T., et al. Polysaccharide antibody responses are impaired post bone marrow transplantation for severe combined immunodeficiency, but not other primary immunodeficiencies. Bone Marrow Transplant 32 2 (2003) 225-229
68. Booth C., Ribeil J.A., Audat F., et al. CD34 stem cell top-ups without conditioning after initial haematopoietic stem cell transplantation for correction of incomplete haematopoietic and immunological recovery in severe congenital immunodeficiencies. Br J Haematol 135 4 (2006) 533-537
69. André-Schmutz I., Six E., Bonhomme D., et al. Shortening the immunodeficient period after hematopoietic stem cell transplantation. Immunol Res 44 1 (2009) 54-60
70. Dvorak C.C., Hung G.Y., Horn B., et al. Megadose CD34 cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation. Biol Blood Marrow Transplant 14 10 (2008) 1125-1133
71. Rachamim N., Gan J., Segall H., et al. Tolerance induction by "megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 65 10 (1998) 1386-1393
72. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 5562 (2002) 2097
73. Bachar-Lustig E., Reich-Zeliger S., and Reisner Y. Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose. Blood 102 6 (2003) 1943
74. Edelshtein Y., Ophir E., Bachar-Lustig E., et al. Ex-vivo acquisition of central memory phenotype is critical for tolerance induction by donor anti-3rd party CD8 T cells in allogeneic bone marrow transplantation. Blood (ASH Annual Meeting Abstracts) 112 (2008) 2323
75. Yu P., Xiong S., He Q., et al. Induction of allogeneic mixed chimerism by immature dendritic cells and bone marrow transplantation leads to prolonged tolerance to major histocompatibility complex disparate allografts. Immunology 127 4 (2009) 500-511